Research ethics and international epidemic response: The case of ebola and marburg hemorrhagic fevers

Public Health Ethics

Volumn 2, Issue 1, 2009, Pages 7-29

  Calain, Philippe ^a,c   Fiore, Nathalie ^a   Poncin, Marc ^a   Hurst, Samia A ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c Méecins Sans Frontiéres ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; CLINICAL FEATURE; CONFIDENTIALITY; COORDINATION; EPIDEMIC; FILOVIRUS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; INFORMATION PROCESSING; INFORMED CONSENT; INSTITUTIONAL REVIEW; ISOLATION PROCEDURE; MEDICAL ETHICS; MEDICAL EXPERT; MEDICINE; NONHUMAN; PATIENT CARE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVACY; PUBLIC HEALTH; QUESTIONNAIRE; RESEARCH ETHICS; REVIEW; SANITATION; VIRUS HEMORRHAGIC FEVER;

EID: 77953448076     PISSN: 17549973     EISSN: 17549981     Source Type: Journal    
DOI: 10.1093/phe/phn037     Document Type: Review

References (103)

1. Amblard, J., Obiang, P., Edzang, S. et al. (1997). Identification of the Ebola Virus in Gabon in 1994. Lancet, 349, 181-182.
2. Baize, S., Leroy, E.M.,Georges,A. J. et al. (2002). Inflammatory Responses in Ebola Virus-Infected Patients. Clinical and Experimental Immunology, 128, 163-168.
3. Baize, S., Leroy, E. M., Georges-Courbot, M. C. et al. (1999). Defective Humoral Responses and Extensive Intravascular Apoptosis Are Associated with Fatal Outcome in Ebola Virus-Infected Patients. Nature Medicine, 5, 423-426.
4. Bausch, D. G., Borchert, M., Grein, T. et al. (2003). Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo. Emerging Infectious Diseases, 9, 1531-1537.
5. Bausch,D.G.,Feldmann,H.,Geisbert, T.W. et al. andthe Winnipeg Filovirus Clinical Working Group. (2007). Outbreaks of Filovirus Hemorrhagic Fever: Time to Refocus on the Patient. Journal of Infectious Diseases, 196(suppl. 2), S136-S141.
6. Bausch, D. G., Nichol, S. T., Muyembe-Tamfum, J. J. et al. and International Scientific and Technical Committee forMarburgHemorrhagic Fever Control in the Democratic Republic of the Congo. (2006). Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of Virus. New England Journal of Medicine, 355, 909-919.
7. Bausch, D. G., Sprecher, A. G., Jeffs, B. et al. (2008). Treatment ofMarburg and EbolaHemorrhagic Fevers: A Strategy for Testing New Drugs and Vaccines under OutbreakConditions.AntiviralResearch, 78, 150-161.
8. Bausch, D. G., Towner, J. S., Dowell, S. F. et al. (2007). Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites. Journal of Infectious Diseases, 196(suppl. 2), S142-S147.
9. Bensimon, C.M.,Tracy,C. S., Bernstein,M. et al. (2007). A Qualitative Study of the Duty to Care in Communicable Disease Outbreaks. Social Science and Medicine, 65, 2566-2575.
10. Bertherat, E., Talarmin, A. and Zeller, H. (1999). République Démocratique du Congo: entre guerre civile et virus Marburg. Comité International de Coordination Technique et Scientifique de l'Epidémie de Durba. Médecine Tropicale, 59, 201-204.
11. Bitekyerezo,M., Kyobutungi, C., Kizza, R. et al. (2002). The Outbreak and Control of Ebola Viral Haemorrhagic Fever in a Ugandan Medical School. Tropical Doctor, 32, 10-15.
12. Borchert, M., Mulangu, S., Lefevre, P. et al. (2007). Use of Protective Gear and the Occurrence of Occupational Marburg Hemorrhagic Fever in Health Workers fromWatsa Health Zone, Democratic Republic of the Congo. Journal of Infectious Diseases, 196(suppl. 2), S168-S175.
13. Borchert, M., Mulangu, S., Swanepoel, R. et al. (2006). Serosurvey onHousehold Contacts ofMarburgHemorrhagic Fever Patients. Emerging Infectious Diseases, 12, 433-439.
14. Boumandouki,P., Formenty,P.,Epelboin, A. et al. (2005). Prise en charge des malades et des défunts lors de lé́pidémie de fievre hémorragique due au virus Ebola d'octobre a décembre 2003 au Congo. Bulletin de la Société de Pathologie Exotique, 98, 218-223.
15. Busico, K.M.,Marshall, K. L.,Ksiazek,T.G. et al. (1999). Prevalence of IgG Antibodies to Ebola Virus in Individuals during an Ebola Outbreak, Democratic Republic of the Congo, 1995. Journal of Infectious Diseases, 179(suppl. 1), S102-S107.
16. Bwaka, M. A., Bonnet, M. J.,Calain, P. et al. (1999). Ebola Hemorrhagic Fever in Kikwit, Democratic Republic of the Congo: Clinical Observations in 103 Patients. Journal of Infectious Diseases, 179(suppl. 1), S1-S7.
17. Calain, P. (2007). Exploring the International Arena of Global Public Health Surveillance. Health Policy and Planning, 22, 13-20.
18. Centers for Disease Control and Prevention, United States of America. 1999. Guidelines for Defining Public Health Research and Public Health Non-Research. Available from: http://www.cdc.gov/od/science/regs/hrpp/ researchdefinition.htm [accessed 9 June 2008].
19. Charlton, B. G. (1993). Public Health Medicine - A Different Kind of Ethics? Journal of the Royal Society of Medicine, 86, 194-195.
20. CIOMS. (1991). International Guidelines for Ethical Review of Epidemiological Studies. Geneva: CIOMS.
21. CIOMS. (2008). International Ethical Guidelines for Epidemiological Studies. Geneva: CIOMS.
22. Coeur, C. (2007). Mission Report, Bundibugyo, 5-24 December 2007. Médecins Sans Frontieres. Unpublished. Colebunders, R., Tshomba, A., Van Kerkhove, M. D. et al. and International Scientific and Technical Committee 'DRC Watsa/Durba 1999 Marburg Outbreak
23. Investigation Group'. (2007). Marburg Hemorrhagic Fever in Durba and Watsa, Democratic Republic of the Congo: Clinical Documentation, Features of Illness, and Treatment. Journal of Infectious Diseases, 196(suppl. 2), S148-S153.
24. Dawson, A. andVerweij, M. (2008). PublicHealth Ethics: A Manifesto. Public Health Ethics, 1, 1-2.
25. De Roo, A., Ado, B., Rose, B. et al. (1998). Survey Among Survivors of the 1995 Ebola Epidemic in Kikwit,DemocraticRepublic ofCongo: Their Feelings and Experiences. Tropical Medicine and International Health, 3, 883-885.
26. Department of Health and Human Services, United States of America. 2007. Code of Federal Regulations, Title 45, part 46, Subpart A: Federal Policy for the Protection of Human Subjects. Revised June 23, 2005. Available from: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm [accessed 9 June 2008].
27. Department of Health and Human Services, Office for Human Research Protections (OHRP), United States of America. 63 FR 60364-60367, November 9, 1998. Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) through an Expedited Review Procedure. Available from: http: //www.hhs.gov/ohrp/humansubjects/guidance/ expedited98.htm [accessed 16 November 2008].
28. Diallo, D. A., Doumbo, O. K., Plowe, C. V. et al. (2005). Community Permission for Medical Research in Developing Countries. Clinical Infectious Diseases, 41, 255-259.
29. Dowell, S. F., Mukunu, R., Ksiazek, T. G. et al. (1999). Transmission of EbolaHemorrhagic Fever: A Study of Risk Factors in Family Members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies a Kikwit. Journal of Infectious Diseases, 179(suppl. 1), S87-S91.
30. Dwyer, J. and Tsai, D. F. (2008). Developing the Duty to Treat: HIV, SARS, and the Next Epidemic. Journal of Medical Ethics, 34, 7-10.
31. Epelboin, A., Formenty, P., Anoko, J. et al. (2008). Humanisation and Informed Consent for People and Populations during Responses to VHF in Central Africa (2003-2008). Humanitarian Stakes, 1, 25-37.
32. Feldmann, H., Jones, S. M., Daddario-DiCaprio K. M. et al. (2007). Effective Post-Exposure Treatment of Ebola Infection. PloS Pathogens, 3, e2.
33. Fidler, D. P. (2005). From International Sanitary Conventions to Global Health Security: The New International Health Regulations. Chinese Journal of International Law, 4, 325-392.
34. Fidler, D. P. (2008). Influenza Virus Samples, International Law, and Global Health Diplomacy. Emerging Infectious Diseases, 14, 88-94.
35. Formenty, P., Epelboin, A., Allarangar, Y. et al. (2005). Séminaire de formation des formateurs et dánalyse des 'epidémies de fievre hémorrhagique due au virus Ebola en Afrique centrale de 2001 a 2004. Bulletin de la Société de Pathologie Exotique, 98, 244- 254.
36. Formenty, P., Leroy, E. M., Epelboin, A. (2006). Detection of Ebola Virus in Oral Fluid Specimens during Outbreaks of Ebola Virus Hemorrhagic Fever in the Republic of Congo. Clinical Infectious Diseases, 42, 1521-1526.
37. Francesconi, P., Yoti, Z., Declich. S et al. (2003). Ebola Hemorrhagic Fever Transmission and Risk Factors of Contacts, Uganda. Emerging Infectious Diseases, 9, 1430-1437.
38. Garrett, L. (2001).Betrayal ofTrust: TheCollapse ofHealth Systems. Oxford University Press.
39. Georges, A. J., Leroy, E. M., Renaut, A. A. et al. (1999). EbolaHemorrhagic Fever Outbreaks in Gabon, 1994- 1997: Epidemiologic and Health Control Issues. Journal of Infectious Diseases, 179(suppl. 1), S65-S75.
40. Georges-Courbot, M. C., Lu, C. Y., Lansoud-Soukate, J. et al. (1997a). Isolation and Partial Molecular Characterisation of a Strain of Ebola Virus during a Recent Epidemic of ViralHaemorrhagic Fever in Gabon. Lancet, 349, 181.
41. Georges-Courbot, M. C., Sanchez, A., Lu, C. Y. et al. (1997b). Isolation and Phylogenetic Characterization of Ebola Viruses Causing Different Outbreaks in Gabon. Emerging Infectious Diseases, 3, 59-62.
42. Gray, J.D. (2001). The Problem ofConsent in Emergency Medicine Research. Canadian Journal of Emergency Medicine, 3, 213-218.
43. Hewlett, B. S., Epelboin, A., Hewlett, B. L. et al. (2005). Medical Anthropology and Ebola in Congo: Cultural Models and Humanistic Care. Bulletin de la Société de Pathologie Exotique, 98, 230-236.
44. Hurst, S. A. (2008). Vulnerability in Research and Health Care; Describing the Elephant in the Room? Bioethics, 22, 191-202.
45. Hutchinson, K. L. and Rollin, P. E. (2007). Cytokine and Chemokine Expression in Humans Infected with Sudan Ebola Virus. Journal of Infectious Diseases, 196(suppl. 2), S357-S363.
46. Jezek, Z., Szczeniowski, M. Y., Muyembe-Tamfum, J. J. et al. (1999). Ebola between Outbreaks: Intensified Ebola Hemorrhagic Fever Surveillance in the Democratic Republic of the Congo, 1981-1985. Journal of Infectious Diseases, 179(suppl. 1), S60-S64.
47. Kass, N. E., Hyder, A. A., Ajuwon, A. et al. (2007). The Structure and Function of Research Ethics Committees in Africa: A Case Study. PLoS Medicine, 4, e3. Khan, A. S., Tshioko, F. K., Heymann, D. L. et al. (1999). The Reemergence of Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies aKikwit. Journal of Infectious Diseases, 179(suppl. 1), S76-S86.
48. Kibadi, K., Mupapa, K., Kuvula, K. et al. (1999). Late Ophthalmologic Manifestations in Survivors of the 1995 Ebola Virus Epidemic in Kikwit, Democratic Republic of the Congo. Journal of Infectious Diseases, 179(suppl. 1), S13-S14.
49. King, N. B. (2002). Security, Disease, Commerce: Ideologies of Postcolonial Global Health. Social Studies of Science, 32, 763-789.
50. Kirigia, J. M.,Wambebe, C. and Baba-Moussa, A. (2005). Status of National Research Bioethics Committees in theWHO African Region. BMCMedical Ethics, 6, 10- 48.
51. Ksiazek, T. G., Rollin, P. E.,Williams, A. J. et al. (1999a). Clinical Virology of Ebola Hemorrhagic Fever (EHF): Virus,VirusAntigen, andIgGandIgMAntibody Findings among EHF Patients in Kikwit, Democratic Republic of the Congo, 1995. Journal of Infectious Diseases, 179(suppl. 1), S177-S187.
52. Ksiazek, T. G., West, C. P., Rollin, P. E. et al. (1999b). ELISA for the Detection of Antibodies to Ebola Viruses. Journal of Infectious Diseases, 179(suppl. 1), S192-S198.
53. Lee, S. H. (2005). The SARS Epidemic inHong Kong-A Human Calamity in the 21st Century. Methods of Information in Medicine, 44, 293-298.
54. Leroy, E. M., Baize, S., Debre, P. et al. (2001). Early Immune Responses Accompanying Human Asymptomatic Ebola Infections. Clinical and Experimental Immunology, 124, 453-460.
55. Leroy,E.M., Baize, S.,Lu,C. Y. et al. (2000a). Diagnosis of EbolaHaemorrhagic Fever by RT-PCR in an Epidemic Setting. Journal of Medical Virology, 60, 463-467.
56. Leroy, E. M., Baize, S., Volchkov, V. E. et al. (2000b). Human Asymptomatic Ebola Infection and Strong Inflammatory Response. Lancet, 355, 2210-2215.
57. Leroy, E. M., Baize, S., Mavoungou, E. et al. (2002). Sequence Analysis of the GP, NP, VP40 and VP24 Genes of Ebola Virus Isolated from Deceased, Surviving and Asymptomatically Infected Individuals during the 1996 Outbreak in Gabon:Comparative Studies and Phylogenetic Characterization. Journal of General Virology, 83(Pt 1), 67-73.
58. Lie, R. K., Emanuel, E. and Wendler, D. (2004). The Standard of Care Debate: The Declaration of Helsinki versus the International Consensus Opinion. Journal of Medical Ethics, 30, 190-193.
59. Lucht, A., Formenty, P., Feldmann, H. et al. (2007). Development of an Immunofiltration-based Antigen- Detection Assay for Rapid Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 196(suppl. 2), S184-S192.
60. MacQueen,K.M. and Buehler, J.W. (2004). Ethics, Practice, and Research in Public Health. American Journal of Public Health, 94, 928-931.
61. Maruyama, T., Parren, P. W., Sanchez, A. et al. (1999a). Recombinant Human Monoclonal Antibodies to Ebola Virus. Journal of Infectious Diseases, 179(suppl. 1), S235-9.
62. Maruyama, T., Rodriguez, L. L., Jahrling, P. B. et al. (1999b). Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection. Journal of Virology, 73, 6024-6030.
63. Mupapa, K., Massamba, M., Kibadi, K. et al. (1999a). Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients. International Scientific and Technical Committee. Journal of Infectious Diseases, 179(suppl. 1), S18-S23.
64. Mupapa, K., Mukundu,W., Bwaka, M. A. et al. (1999b). Ebola Hemorrhagic Fever and Pregnancy. Journal of Infectious Diseases, 179(suppl. 1), S11-S12.
65. Mupere, E., Kaducu, O. F. and Yoti, Z. (2001). Ebola Haemorrhagic Fever among Hospitalised Children and Adolescents in Northern Uganda: Epidemiologic and Clinical Observations. African Health Sciences, 1, 60-65.
66. Ndambi, R., Akamituna, P., Bonnet, M. J. et al. (1999). Epidemiologic and Clinical Aspects of the Ebola Virus Epidemic in Mosango, Democratic Republic of the Congo, 1995. Journal of Infectious Diseases, 179(suppl. 1), S8-S10.
67. Nkoghe, D., Formenty, P., Leroy, E. M. et al. (2005a). Plusieurs 'epidémies de fievre hémorragique due au virus Ebola au Gabon, d'octobre 2001 a avril 2002. Bulletin de la Société de Pathologie Exotique, 98, 224- 229.
68. Nkoghe, D., Nnegue, S., Mve, M. T. et al. (2005b). Cas isolé de fievre hémorragique survenu au Gabon en 2002 pendant lé́pidémie d'Ebola mais distant des régions 'epidémiques. Médecine Tropicale, 65, 349- 354.
69. Onyango, C. O., Opoka, M. L., Ksiazek, T. G. et al. (2007). Laboratory Diagnosis of Ebola Hemorrhagic Fever during an Outbreak in Yambio, Sudan, 2004. Journal of Infectious Diseases, 196(suppl. 2), S193- S198.
70. Prehaud, C., Hellebrand, E., Coudrier, D. et al. (1998). Recombinant Ebola Virus Nucleoprotein and Glycoprotein (Gabon 94 Strain) Provide New Tools for the Detection ofHuman Infections. Journal of General Virology, 79(Pt 11), 2565-2572.
71. Reid, L. (2005). Diminishing Returns? Risk and the Duty to Care in the SARS Epidemic. Bioethics, 19, 348- 361.
72. Richards, G. A., Murphy, S., Jobson, R. et al. (2002). Unexpected Ebola Virus in a Tertiary Setting: Clinical and EpidemiologicAspects.Critical CareMedicine, 28, 240-244.
73. Rodriguez, L. L., De Roo, A., Guimard, Y. et al. (1999). Persistence and Genetic Stability of EbolaVirus during the Outbreak in Kikwit, Democratic Republic of the Congo, 1995. Journal of Infectious Diseases, 179(suppl. 1), S170-S176.
74. Roels, T. H., Bloom, A. S., Buffington, J. et al. (1999). EbolaHemorrhagic Fever,Kikwit,DemocraticRepublic of the Congo, 1995: Risk Factors for Patients without aReported Exposure. Journal of InfectiousDiseases, 179(suppl. 1), S92-S97.
75. Rollin, P. E., Bausch,D. G. and Sanchez, A. (2007). Blood Chemistry Measurements and D-Dimer Levels Associated with Fatal and Nonfatal Outcomes in Humans Infected with Sudan Ebola Virus. Journal of Infectious Diseases, 196 (suppl. 2), S364-S371.
76. Rowe, A. K., Bertolli, J., Khan, A. S. et al. (1999). Clinical, Virologic, and Immunologic Follow-Up of Convalescent EbolaHemorrhagic Fever Patients and Their Household Contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies a Kikwit. Journal of Infectious Diseases, 179(suppl. 1), S28-S35.
77. Ruderman, C.,Tracy,C.S., Bensimon,C.M. et al. (2006). On Pandemics and the Duty to Care: Whose Duty? Who Cares? BMC Medical Ethics, 7, 5.
78. Saijo, M., Niikura, M., Morikawa, S. et al. (2001). Enzyme-Linked ImmunosorbentAssays forDetection of Antibodies to Ebola and Marburg Viruses Using Recombinant Nucleoproteins. Journal of Clinical Microbiology, 39, 1-7.
79. Sanchez, A., Ksiazek, T. G., Rollin, P. E. et al. (1999). Detection and Molecular Characterization of Ebola Viruses Causing Disease in Human and Nonhuman Primates. Journal of Infectious Diseases, 179(suppl. 1), S164-S169.
80. Sanchez, A., Lukwiya,M., Bausch, D. et al. (2004). Analysis of Human Peripheral Blood Samples from Fatal and Nonfatal Cases of Ebola (Sudan) Hemorrhagic Fever: Cellular Responses, Virus Load, and Nitric Oxide Levels. Journal of Virology, 78, 10370-10377.
81. Sanchez, A., Wagoner, K. E. and Rollin, P. E. (2007). Sequence-based Human Leukocyte Antigen-B Typing of Patients Infected with Ebola Virus in Uganda in 2000: Identification of Alleles Associated with Fatal and Nonfatal Disease Outcomes. Journal of Infectious Diseases, 196(suppl. 2), S329-S336.
82. Sedyaningsih, E. R., Isfandari, S., Soendoro, T. et al. (2008). Towards Mutual Trust, Transparency and Equity inVirus SharingMechanism:TheAvian Influenza Case of Indonesia. Annals Academy ofMedicine Singapore, 37, 482-488.
83. Singer, P. A., Benatar, S. R., Bernstein, M. et al. (2003). Ethics and SARS: Lessons from Toronto. British Medical Journal, 327, 1342-1344.
84. Singh, J. A., Upshur, R. and Padayatchi, N. (2007). XDRTB in South Africa: No Time for Denial or Complacency. PLoS Medicine, 4, e50.
85. Tomori, O., Bertolli, J., Rollin, P. E. et al. (1999). Serologic Survey amongHospital andHealth CenterWorkers during the Ebola Hemorrhagic Fever Outbreak in Kikwit,DemocraticRepublic of theCongo, 1995. Journal of Infectious Diseases, 179(suppl. 1), S98-S101.
86. Towner, J. S., Khristova, M. L., Sealy, T. K. et al. (2006). Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola. Journal of Virology, 80, 6497-6516.
87. Towner, J. S., Rollin, P. E., Bausch, D. G. et al. (2004). Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome. Journal of Virology, 78, 4330-4341.
88. Towner, J. S., Sealy, T. K., Ksiazek, T. G. et al. (2007). High-Throughput Molecular Detection of Hemorrhagic Fever Virus Threats with Applications for Outbreak Settings. Journal of Infectious Diseases, 196(suppl. 2), S205-S212.
89. Towner, J. S., Sealy, T. K., Khristova, M. L. et al. (2008). Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda. PloS Pathogens, 4, e1000212.
90. Upshur, R. E. G., Lavery, J. V. and Tindana, P. O. (2007). Taking Tissue Seriously Means Taking Communities Seriously. BMC Medical Ethics, 8, 11.
91. Villinger,F.,Rollin, P. E.,Brar, S. S. et al. (1999).Markedly Elevated Levels of Interferon (IFN)-Gamma, IFNAlpha, Interleukin (IL)-2, IL-10, and Tumor Necrosis Factor-Alpha Associated with Fatal Ebola Virus Infection. Journal of Infectious Diseases, 179(suppl. 1), S188-S191.
92. Weidmann, M., Hufert, F. T. and Sall, A. A. (2007). Viral Load among Patients Infected with Marburgvirus in Angola. Journal of Clinical Virology, 39, 65-66.
93. Weijer, C. (2004). The Ethical Analysis of Risk in Intensive Care Unit Research. Critical Care, 8, 85-86.
94. Wendler, D., Pace, C., Talisuna, A. O. et al. (2005). Research on Stored Biological Samples: The Views of Ugandans. IRB, 27, 1-5.
95. World Health Organization. (2005a). Revision of the International Health Regulations. Fifty-Eighth
96. World Health Assembly. DocumentWHA58.3. Available from: http://www.who.int/gb/ebwha/pdffiles/WHA58/A58 4-en.pdf [accessed 9 June 2008].
97. WorldHealth Organization. (2005b). Guiding Principles for International Outbreak Alert and Response. Available from: http://www.who.int/csr/ outbreaknetwork/guidingprinciples/en/print.html [accessed 9 June 2008].
98. World Health Organization. (2007a). Ethical Considerations in Developing a Public Health Response to Pandemic Influenza. Document WHO/CDS/EPR/ GIP/2007.2. Geneva.
99. World Health Organization. (2007b). Ebola Haemorrhagic Fever in the Democratic Republic of the Congo-Update 2 (20 September 2007). Available from: http://www.who.int/csr/don/20070920/en/index.html [accessed 9 June 2008].
100. World Health Organization. (2008). End of Ebola Outbreak in Uganda (20 February 2008). Available from: http://www.who.int/csr/don/20070220b/en/index. html [accessed 9 June 2008].
101. World Medical Association. (2008). Declaration of Helsinki, 6th revision. Available from: http://www.wma.net/e/policy/b3.htm [accessed 16 November 2008].
102. Zaki, S. R., Shieh, W-J, Greer, P. W. et al. for the Commission deLutte contre les Epidémies a Kikwit. A Novel Immunohistochemical Assay for the Detection of Ebola Virus in Skin: Implications for Diagnosis, Spread, and Surveillance of EbolaHemorrhagic Fever. Journal of Infectious Diseases, 179(suppl. 1), S36-S47.
103. Zhai, J., Palacios, G., Towner, J. S. et al. (2007). Rapid Molecular Strategy for Filovirus Detection and Characterization. Journal of ClinicalMicrobiology, 45, 224- 226.